Effect of antihistamine up-dosing in chronic urticaria.

Chronic urticaria has an important impact upon patient quality of life, and no treatment has yet been developed capable of effectively controlling the disease. The most recent guidelines recommend the use of non-sedating antihistamines at high doses as second-step therapy before resorting to other treatments. The present review examines the studies published to date on the use of H1 antihistamines at doses higher than those indicated as therapeutic doses in chronic urticaria. Most of the studies report no significant differences among the studied doses-only a tendency towards increased response on elevating the dose. There are no clinically well designed, randomized double-blind trials comparing efficacy between therapeutic doses and doses higher than those indicated in the corresponding Summary of Product Characteristics. Likewise, there are insufficient data to conduct a meta-analysis and thus classify the degree of evidence of the few available studies, which moreover present contradictory results. At present, the prescription of high-dose H1 antihistamines is based only on experts opinion. However, considering the high safety profile of these drugs, it would be a good option to evaluate their efficacy at high doses, before moving on to other therapeutic steps.

[1]  M. Maurer,et al.  Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. , 2010, The Journal of allergy and clinical immunology.

[2]  J. Bousquet,et al.  Risk of first‐generation H1‐antihistamines: a GA2LEN position paper , 2010, Allergy.

[3]  T. Zuberbier,et al.  Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi‐centre, double‐blind, randomized, placebo‐controlled study , 2010, Allergy.

[4]  Todor A Popov,et al.  The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. , 2010, The Journal of allergy and clinical immunology.

[5]  H. Schünemann,et al.  EAACI/GA²LEN/EDF/WAO guideline: management of urticaria , 2009, Allergy.

[6]  M. Maurer,et al.  The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo‐ controlled treatment with rupatadine 10 and 20 mg , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  T. Zuberbier,et al.  High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. , 2009, The Journal of allergy and clinical immunology.

[8]  A. Kaplan What the first 10,000 patients with chronic urticaria have taught me: a personal journey. , 2009, The Journal of allergy and clinical immunology.

[9]  R. Zeldin,et al.  Treatment of chronic autoimmune urticaria with omalizumab. , 2008, The Journal of allergy and clinical immunology.

[10]  S. Spector,et al.  Omalizumab also successful in chronic urticaria. , 2008, The Journal of allergy and clinical immunology.

[11]  C. Grattan,et al.  Guidelines for evaluation and management of urticaria in adults and children , 2007, The British journal of dermatology.

[12]  L. Dubertret,et al.  Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. , 2007, European journal of dermatology : EJD.

[13]  E. Arnáiz,et al.  Rupatadine in the treatment of chronic idiopathic urticaria: a double‐blind, randomized, placebo‐controlled multicentre study , 2007, Allergy.

[14]  R. Asero Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above‐licensed doses , 2006, Clinical and experimental dermatology.

[15]  G. Vena,et al.  Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. , 2006, Journal of the American Academy of Dermatology.

[16]  T. Zuberbier,et al.  EAACI/GA2LEN/EDF guideline: management of urticaria , 2006, Allergy.

[17]  P. Auquier,et al.  Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life , 2005, The British journal of dermatology.

[18]  F. Simons Advances in H1-antihistamines. , 2004, The New England journal of medicine.

[19]  A. Kaplan Chronic urticaria: pathogenesis and treatment. , 2004, The Journal of allergy and clinical immunology.

[20]  G. W. Canonica,et al.  Consensus group on new‐generation antihistamines (CONGA): present status and recommendations , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[21]  F. Simons,et al.  Clinical pharmacology of H1-antihistamines in the skin. , 2002, The Journal of allergy and clinical immunology.

[22]  A. Kaplan,et al.  Secretion of Cytokines, Histamine and Leukotrienes in Chronic Urticaria , 2002, International Archives of Allergy and Immunology.

[23]  R. Leurs,et al.  H1‐antihistamines: inverse agonism, anti‐inflammatory actions and cardiac effects , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[24]  A. Kay,et al.  TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. , 2002, The Journal of allergy and clinical immunology.

[25]  P. Seed,et al.  Randomized double‐blind study of cyclosporin in chronic ‘idiopathic’ urticaria , 2000, The British journal of dermatology.

[26]  H. Nelson,et al.  Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[27]  A. Kaplan,et al.  A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. , 1999, The Journal of allergy and clinical immunology.

[28]  M. Emanuel Histamine and the antiallergic antihistamines: a history of their discoveries , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[29]  M. Morgan,et al.  The impact of chronic urticaria on the quality of life , 1997, The British journal of dermatology.

[30]  J. Q. Rosso,et al.  Chronic urticaria: do urticaria nonexperts implement treatment guidelines? A survey of adherence to published guidelines by nonexperts , 2010 .

[31]  T. Zuberbier,et al.  Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria : a multi-centre , double-blind , random-ized , placebo-controlled study , 2010 .

[32]  M. Ferrer Epidemiology, healthcare, resources, use and clinical features of different types of urticaria. Alergológica 2005. , 2009, Journal of investigational allergology & clinical immunology.

[33]  Suephy C. Chen,et al.  Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. , 2008, Archives of dermatology.

[34]  M. T. Caballero,et al.  Epidemiology of urticaria in Spain. , 2004, Journal of investigational allergology & clinical immunology.

[35]  T. Zuberbier,et al.  Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. , 1996, Dermatology.